Drug Description in Trials / DrugBank / KEGG DRUG

  

Search results

No. Drug (Description in trials) DrugBank KEGG DRUG KEGG GENES KEGG PATHWAY Disease ID
1Soliris 300[1] Eculizumab[1] Eculizumab 💬 [1] C5 💬 [11] Alcoholic liver disease, Complement and coagulation cascades, Coronavirus disease - COVID-19, Herpes simplex virus 1 infection, Neuroactive ligand-receptor interaction, Neutrophil extracellular trap formation, Pertussis, Prion disease, Regulation of actin cytoskeleton, Staphylococcus aureus infection, Systemic lupus erythematosus 💬[1] 62 💬
2SOLIRIS 300 mg concentrado para solución para perfusión[1] Eculizumab[1] Eculizumab 💬 [1] C5 💬 [11] Alcoholic liver disease, Complement and coagulation cascades, Coronavirus disease - COVID-19, Herpes simplex virus 1 infection, Neuroactive ligand-receptor interaction, Neutrophil extracellular trap formation, Pertussis, Prion disease, Regulation of actin cytoskeleton, Staphylococcus aureus infection, Systemic lupus erythematosus 💬[1] 109 💬
3Soliris 300 mg concentrate for solution for infusion[1] Eculizumab[1] Eculizumab 💬 [1] C5 💬 [11] Alcoholic liver disease, Complement and coagulation cascades, Coronavirus disease - COVID-19, Herpes simplex virus 1 infection, Neuroactive ligand-receptor interaction, Neutrophil extracellular trap formation, Pertussis, Prion disease, Regulation of actin cytoskeleton, Staphylococcus aureus infection, Systemic lupus erythematosus 💬[1] 62 💬
4Soliris 300mg/30ml[1] Eculizumab[1] Eculizumab 💬 [1] C5 💬 [11] Alcoholic liver disease, Complement and coagulation cascades, Coronavirus disease - COVID-19, Herpes simplex virus 1 infection, Neuroactive ligand-receptor interaction, Neutrophil extracellular trap formation, Pertussis, Prion disease, Regulation of actin cytoskeleton, Staphylococcus aureus infection, Systemic lupus erythematosus 💬[1] 62 💬